Literature DB >> 27649656

The SUMO-specific protease SENP5 controls DNA damage response and promotes tumorigenesis in hepatocellular carcinoma.

Z-L Jin1, H Pei, Y-H Xu, J Yu, T Deng.   

Abstract

OBJECTIVE: SUMOylation plays critical roles in a variety of physiological and pathological processes including tumorigenesis. SUMOylation is a reversible process which is mediated by the SENP (Sentrin/SUMO-specific protease) family to remove SUMO from conjugated substrates. SENP5 has been reported to play critical roles in the control of several cancers including breast cancer, osteosarcoma and oral squamous cell carcinoma. In this study, we uncovered a role of SENP5 in promoting tumorigenesis process in hepatocellular carcinoma (HCC) via regulating DNA damage response.
MATERIALS AND METHODS: The mRNA and protein levels of SENP5 in 10 pairs of HCC samples were determined by Realtime PCR and Western blot, respectively. SiRNAs were used to silence the expression of SENP5 in HepG2 cells. Male BALB/c nude mice were used to determine the roles of SENP5 on tumorigenesis. In vivo SUMOylation assay was used to detect the SUMOylation of ATRIP. Immunoprecipitation (IP) was used to detect the interaction between SENP5 and ATRIP.
RESULTS: We found that SENP5 was over-expressed in HCC samples and required for HCC cells proliferation both in vitro and in vivo. SENP5-depleted HepG2 cells exhibited hypersensitivity to IR and etoposide treatment with defective checkpoint activation including decreased activation of ATR and phosphorylation of ATR targets. At the molecular level, we found that SENP5 interacted with ATRIP and promoted ATRIP deSUMOylation.
CONCLUSIONS: Overall, our data suggest that SENP5 is required for HCC cell growth and might be a promising drug target for HCC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27649656

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  11 in total

1.  P53 suppresses SENP3 phosphorylation to mediate G2 checkpoint.

Authors:  Yang Wang; Jing Tian; Chao Huang; Jiao Ma; Gaolei Hu; Yalan Chen; Tianshi Wang; Rong Cai; Yong Zuo; Hongsheng Tan; Qiuju Fan; Baijun Dong; Wei Xue; Jing Yi; Guoqiang Chen; Jun Tu; Jinke Cheng
Journal:  Cell Discov       Date:  2020-04-21       Impact factor: 10.849

2.  Desumoylase SENP6 maintains osteochondroprogenitor homeostasis by suppressing the p53 pathway.

Authors:  Jianshuang Li; Di Lu; Hong Dou; Huadie Liu; Kevin Weaver; Wenjun Wang; Jiada Li; Edward T H Yeh; Bart O Williams; Ling Zheng; Tao Yang
Journal:  Nat Commun       Date:  2018-01-10       Impact factor: 14.919

3.  P53 suppresses SENP3 phosphorylation to mediate G2 checkpoint.

Authors:  Yang Wang; Jing Tian; Chao Huang; Jiao Ma; Gaolei Hu; Yalan Chen; Tianshi Wang; Rong Cai; Yong Zuo; Hongsheng Tan; Qiuju Fan; Baijun Dong; Wei Xue; Jing Yi; Guoqiang Chen; Jun Tu; Jinke Cheng
Journal:  Cell Discov       Date:  2020-04-21       Impact factor: 10.849

4.  Inhibition of SUMO2/3 antagonizes isoflurane-induced cancer-promoting effect in hepatocellular carcinoma Hep3B cells.

Authors:  Peng Wang; Na Xue; Chunyan Zhang; Shimin Shan; Zhongmin Jiang; Wenhan Wu; Xiaozhi Liu
Journal:  Oncol Lett       Date:  2021-02-10       Impact factor: 2.967

Review 5.  SUMOylation Wrestles With the Occurrence and Development of Breast Cancer.

Authors:  Yuanyuan Qin; Hong Yuan; Xu Chen; Xinyi Yang; Zhengcao Xing; Yajie Shen; Wanying Dong; Siming An; Yitao Qi; Hongmei Wu
Journal:  Front Oncol       Date:  2021-04-21       Impact factor: 6.244

Review 6.  The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer.

Authors:  Nicole E Pellegrino; Arcan Guven; Kayleigh Gray; Punit Shah; Gargi Kasture; Maria-Dorothea Nastke; Anjan Thakurta; Stephane Gesta; Vivek K Vishnudas; Niven R Narain; Michael A Kiebish
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

7.  Recurrent HBV Integration Targets as Potential Drivers in Hepatocellular Carcinoma.

Authors:  Selena Y Lin; Adam Zhang; Jessica Lian; Jeremy Wang; Ting-Tsung Chang; Yih-Jyh Lin; Wei Song; Ying-Hsiu Su
Journal:  Cells       Date:  2021-05-23       Impact factor: 6.600

Review 8.  The post-translational modification, SUMOylation, and cancer (Review).

Authors:  Zhi-Jian Han; Yan-Hu Feng; Bao-Hong Gu; Yu-Min Li; Hao Chen
Journal:  Int J Oncol       Date:  2018-02-22       Impact factor: 5.650

9.  SUMO1 modification of histone H4 is involved in the pathogenesis of nodular lymphocyte predominant Hodgkin lymphoma.

Authors:  Hongyu Li; Li Guo; Bingyu Li; Xun Li
Journal:  Transl Cancer Res       Date:  2020-07       Impact factor: 1.241

Review 10.  Epigenetic remodelling in human hepatocellular carcinoma.

Authors:  Maria Rita Braghini; Oriana Lo Re; Ilaria Romito; Maite G Fernandez-Barrena; Barbara Barbaro; Silvia Pomella; Rossella Rota; Manlio Vinciguerra; Matias A Avila; Anna Alisi
Journal:  J Exp Clin Cancer Res       Date:  2022-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.